---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-425647"
form_type: "8-K"
ticker: "RAPP"
cik: "0002012593"
company_name: "Rapport Therapeutics, Inc."
filed_at: "2026-10-20T10:05:17+00:00"
generated_at: "2026-10-20T10:10:08.298502+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Rapport's RAP-219 hits Phase 2 primary endpoint in bipolar mania (3.1-pt YMRS gain, p=0.045)

## Summary
- Phase 2 met primary endpoint: 3.1-point placebo-adjusted YMRS improvement at Week 3 (p=0.045); 15.4-point mean reduction from baseline vs 12.3 on placebo.
- Secondary CGI-BP mania severity improved 0.4 points vs placebo (p=0.024); all 11 YMRS items improved, with 4 reaching nominal significance.
- 253 adults with bipolar I mania enrolled (126 on RAP-219 0.75 mg, 127 placebo); all TEAEs mild or moderate, no SAEs; 3.2% vs 0.8% discontinued for TEAE.
- Plans FDA End-of-Phase 2 meeting in Q1 2027 and two Phase 3 bipolar mania trials starting 2H 2027; FOS FOCUS 1/2 enrolling, PGTCS Phase 3 1H 2027.
- $436.1M in cash, equivalents and short-term investments as of June 30, 2026; runway into 2H 2029, beyond FOS Phase 3 topline data.

## SEC filing metadata
- accession: 0001193125-26-425647
- form_type: 8-K
- ticker: RAPP
- cik: 0002012593
- company_name: Rapport Therapeutics, Inc.
- filed_at: 2026-10-20T10:05:17+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2012593/000119312526425647/0001193125-26-425647-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2012593/000119312526425647/d185134d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-425647
- JSON: https://secwatch.observer/filing/0001193125-26-425647.json
- Plain text: https://secwatch.observer/filing/0001193125-26-425647.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.